Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas U Marron

Showing results (11-20 of 91) with videos related to

Pageof 10
Sort By:
Hepatology (Baltimore, Md.)|December 28, 2020
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular CarcinomaDavid J Pinato, Petros Fessas, Gonzalo Sapisochin, et al.
The Journal of Allergy and Clinical Immunology|November 18, 2011
Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokinesThomas U Marron, Monica Martinez-Gallo, Joyce E Yu, et al.
Clinical Immunology (Orlando, Fla.)|July 17, 2010
TLR signaling and effector functions are intact in XLA neutrophilsThomas U Marron, Kaileen Rohr, Monica Martinez-Gallo, et al.
JAMA Oncology|January 22, 2026
Morbidity and Mortality Outcomes of Dupilumab for Cutaneous Immune-Related Adverse EventsBrandon R Block, Jaanvi Mehta, Shayan Owji, et al.
Immunotherapy|December 21, 2016
Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial updateThomas U Marron, Lukas Ronner, Peter E Martin, et al.
Annals of Surgical Oncology|June 12, 2021
Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 AntibodyAlexander J Rossi, Tahsin M Khan, Areeba Saif, et al.
Cancer Treatment Reviews|May 22, 2024
Optimizing care in early phase cancer trials: The role of palliative careFionnuala Crowley, Richard Sheppard, Stephanie Lehrman, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2022
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma - Authors' replyThomas U Marron, Myron E Schwartz, Elizabeth Miller, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2009
Toll-like receptor 7 and 9 defects in common variable immunodeficiencyJoyce E Yu, Adina K Knight, Lin Radigan, et al.
Nature Reviews. Clinical Oncology|February 29, 2024
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinomaJosep M Llovet, Roser Pinyol, Mark Yarchoan, et al.
Pageof 10

Showing results (11-20 of 91) with videos related to

Sort By:
Pageof 10
Hepatology (Baltimore, Md.)|December 28, 2020
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular CarcinomaDavid J Pinato, Petros Fessas, Gonzalo Sapisochin, et al.
The Journal of Allergy and Clinical Immunology|November 18, 2011
Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokinesThomas U Marron, Monica Martinez-Gallo, Joyce E Yu, et al.
Clinical Immunology (Orlando, Fla.)|July 17, 2010
TLR signaling and effector functions are intact in XLA neutrophilsThomas U Marron, Kaileen Rohr, Monica Martinez-Gallo, et al.
JAMA Oncology|January 22, 2026
Morbidity and Mortality Outcomes of Dupilumab for Cutaneous Immune-Related Adverse EventsBrandon R Block, Jaanvi Mehta, Shayan Owji, et al.
Immunotherapy|December 21, 2016
Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial updateThomas U Marron, Lukas Ronner, Peter E Martin, et al.
Annals of Surgical Oncology|June 12, 2021
Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 AntibodyAlexander J Rossi, Tahsin M Khan, Areeba Saif, et al.
Cancer Treatment Reviews|May 22, 2024
Optimizing care in early phase cancer trials: The role of palliative careFionnuala Crowley, Richard Sheppard, Stephanie Lehrman, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2022
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma - Authors' replyThomas U Marron, Myron E Schwartz, Elizabeth Miller, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2009
Toll-like receptor 7 and 9 defects in common variable immunodeficiencyJoyce E Yu, Adina K Knight, Lin Radigan, et al.
Nature Reviews. Clinical Oncology|February 29, 2024
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinomaJosep M Llovet, Roser Pinyol, Mark Yarchoan, et al.
Pageof 10